OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results
Stephen V. Liu(Georgetown University), Martin Reck(German Center for Lung Research), Zoran Andrić(University Hospital Medical Center Bezanijska kosa), Barzin Y. Nabet(Gene Therapy Laboratory), R.B. Caro(Hospital Universitario Virgen del Rocío), Gregory J. Gerstner(Illinois CancerCare), Raffaele Califano(The Christie NHS Foundation Trust), Florian Huemer(Chinese University of Hong Kong), W. Zhang, Marta Batus(Rush University Medical Center), Rafał Dziadziuszko(Gdańsk Medical University), D. Kowalski(National Institute of Oncology), Manika Kaul, M. Siddiqui, G Losonczy(Semmelweis University), J.-S. Lee(Seoul National University Bundang Hospital), Steven Kao(Chris O’Brien Lifehouse), Shunichi Sugawara(Sendai Kousei Hospital), Gilberto de Castro(Instituto do Câncer do Estado de São Paulo), Andrea Veatch(Northwest Medical Specialties), H. Li(Roche (China)), Libor Havel(Chinese University of Hong Kong), S. Morris, Maximilian J. Hochmair(Karl Landsteiner Society)
Cited by 36
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k